Artera Announces Collaboration with Tempus to Expand Access to Personalized Prostate Cancer Treatment

Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S.

Excerpt from the Press Release:

SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, announced today that they will collaborate to expand access to the ArteraAI Prostate Test. Through the collaboration, Tempus and Artera will work together in an exclusive manner to commercialize Artera’s prostate cancer risk stratification test. Tempus is currently connected to more than 50% of all oncologists practicing in the United States.

“We are looking forward to collaborating with Artera to expand access to Artera’s current prostate cancer test,” said Ezra Cohen, MD, Chief Medical Officer at Tempus. “Management of localized prostate cancer has always been a balance between doing too much and not enough. Now, by combining our efforts, we can empower clinicians and patients with critical insights to allow an informed decision at this crucial point in their treatment journey, ensuring that each patient receives the care that is right for them.”

The ArteraAI Prostate Test is an AI-enabled test that provides predictive and prognostic results for patients with localized prostate cancer. The first of its kind, the test provides actionable insights to empower shared decision-making between the patient and clinician to help personalize treatment plans.

Click the button below to read the entire Press Release:

Continue Reading The Press Release